Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI response themes (serious infections, mortality, malignancy, MACE, thrombosis) are supported by the cited label sections. However, at least one dose/indication restriction statement is only partially supported because the evidence anchoring does not clearly reference the label’s explicit dosing/usage limitation section(s).
Category Scores
Accurate Statements
Serious infections may occur; avoid/interrupt tofacitinib if a serious infection develops.
Supported by Warnings and Precautions (5.1) and Administration Instructions (2.2), including instruction to interrupt if a serious/opportunistic infection or sepsis develops.
Increased risk of mortality may occur.
Supported by Warnings and Precautions (5.2).
Malignancy/lymphoproliferative disorders may occur; consider benefits/risks particularly in patients with known malignancy (other than successfully treated NMSC) or current/past smokers.
Supported by Warnings and Precautions (5.3), including the specific qualifier 'other than successfully treated NMSC' and 'current or past smokers.'
Major adverse cardiovascular events (MACE) may occur; discontinue in patients who have experienced MI or stroke.
Supported by Warnings and Precautions (5.4), including discontinuation instruction for MI or stroke.
Thrombosis may occur (including PE, DVT, arterial thrombosis); evaluate promptly and discontinue if symptoms of thrombosis occur; avoid in patients at increased risk.
Supported by Warnings and Precautions (5.5), including prompt evaluation, discontinuation on symptoms, and avoidance in patients at increased risk.
Unsupported Statements
Specific dose statements restricting tofacitinib tablets 10 mg twice daily (or tofacitinib extended-release tablets 22 mg once daily) are not recommended for RA/PsA/AS/pcJIA.
Partially supported. The cited label sections in the AI evaluation are warning sections (5.2–5.4) that reference not-recommended dosing for certain indications, but the response’s audit anchoring does not clearly point to the precise dosing/indication restriction language/location (e.g., a dedicated Dosage and Administration/Not recommended statement for those indications).
Contradictions
Important Omissions
If the full AI response (not provided here) claimed additional elements such as contraindications, boxed warning exact wording/coverage beyond the selected themes, or specific drug-interaction and pediatric details, these were not evaluated from the provided excerpt and may be materially important depending on what the AI response stated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most major safety warning themes are supported by label sections. The main gap is partial support/unclear anchoring for a dose/indication restriction statement rather than a clear contradiction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The dose/indication restriction claim is only partially supported because the audit citations do not clearly reference the label’s explicit dosing/usage limitation section(s) and exact restriction wording for RA/PsA/AS/pcJIA.
Suggested Improvement
Anchor the restriction statement to the exact label location/wording that explicitly states the 'not recommended' dose for RA/PsA/AS/pcJIA (e.g., the specific Dosage/Administration 'not recommended' language or the exact 'dosages are not recommended' statement as presented for those indications).